Core Insights - The company, Yipai Sunshine (02522), announced that its subsidiary, Tianjin Yipai Yingrun Medical Imaging Diagnosis Co., successfully won the bid for the "Tianjin Beichen Hospital Medical Project" on October 24, 2025, marking a significant step in its regional strategy [1][2] - The project is expected to generate annual revenue of tens of millions, indicating substantial progress in the company's strategy of "regional deepening and national radiation" [1] - The project will establish a smart medical sharing platform comprising five modules: regional imaging sharing center, integrated smart laboratory, digital pathology center, health management center, and nuclear medicine center, enhancing resource collaboration and service efficiency [1] Company Strategy - This project represents the company's first comprehensive integration project covering imaging, testing, pathology, nuclear medicine, and health management, showcasing its capabilities in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in the North China region and lay a solid foundation for promoting similar projects in the Beijing-Tianjin-Hebei area [2] - The project is expected to have positive strategic value for the company's long-term development [2]

Core Insights - The company successfully won the bid for the "Tianjin Beichen Hospital Medical Project," marking its first government cooperative regional medical resource integration project in Tianjin, with expected annual revenue reaching tens of millions [1] - The project aims to establish a regional smart medical sharing platform, enhancing the collaboration and service efficiency of medical resources through five key modules [1] - The project reflects the company's comprehensive service capabilities in medical imaging, pathology diagnosis, and health management, gaining recognition from the government and high-end medical institutions [1] Summary by Sections - **Project Overview** - The project is a comprehensive integration initiative covering imaging, testing, pathology, nuclear medicine, and health management, showcasing the company's ability in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in North China and lay a solid foundation for similar projects in the future [2] - **Strategic Importance** - This project is a significant step in the company's "regional deep cultivation, national radiation" strategy, indicating substantial progress [1] - The innovative cooperation model will enable the company to provide standardized operational management systems and technical capabilities to assist hospitals in optimizing resources and improving efficiency [1]

Core Insights - The company, Yimai Sunshine (02522.HK), announced that its subsidiary, Tianjin Yimai Yingrun Medical Imaging Diagnosis Co., Ltd., has successfully won the bid for the "Tianjin Beichen Hospital Medical Project," marking a significant step in its strategy of regional deepening and national radiation [1][2] Group 1 - The project is expected to generate annual revenue of tens of millions, indicating substantial progress in the company's strategy [1] - The project will establish a regional smart medical sharing platform, focusing on five key modules: regional imaging sharing center, smart integrated laboratory, digital pathology center, health management center, and nuclear medicine center [1] - The Beichen Hospital, established in 1963, is a comprehensive hospital with a strong foundation in various specialties, enhancing the project's credibility and potential impact [1] Group 2 - The project represents the company's first comprehensive integration project covering imaging, testing, pathology, nuclear medicine, and health management, showcasing its capabilities in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in the North China region and lay a solid foundation for promoting similar projects in the Beijing-Tianjin-Hebei area [2] - The project is expected to have positive strategic value for the company's long-term development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會認為，該項目作為本集團首個覆蓋影像、檢驗、病理、核醫學及健康管理 的全業態整合型項目，不僅展現了本集團在區域醫療資源協同與智慧化運營方面 的整合能力，更為後續在京津冀地區推廣類似項目奠定了堅實基礎。項目的實施 將進一步強化本集團在華北地區的市場佈局，為後續拓展同類型項目奠定堅實基 礎，對本集團長期發展具有積極戰略價值。 自願公告 業務進展 中標天津市北辰醫院醫療項目 本公告由江西一脈陽光集團股份有限公司（「本公司」），連同其附屬公司統稱（「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，本公司之附屬公司天津一脈盈潤醫學影像診斷有限公司作為聯 合體牽頭方，於2025年10月24日成功中標「天津市北辰醫院醫療項目」（招標編 號：YTKX2025-B-070），並獲取中標通知書。本集團預期將聯同聯合體其他成員 於近期與天津市北辰醫院正式簽署項目合作協議。 該項目為本集團在天津地區 ...

Core Viewpoint - The southbound capital has increased its holdings in Yipai Sunshine (02522.HK) significantly, indicating strong investor interest and confidence in the company's performance [1]. Group 1: Shareholding Changes - On October 22, 2025, southbound capital increased its holdings by 117,500 shares, bringing the total to 128 million shares, which represents 43.35% of the company's issued ordinary shares [1][2]. - Over the past five trading days, there have been four days of net increases, totaling 861,500 shares [1]. - In the last 20 trading days, there were 10 days of net increases, amounting to 1,119,500 shares [1]. Group 2: Company Overview - Jiangxi Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China [2]. - The company operates three segments: imaging center services, imaging solutions, and Yipai cloud services [2]. - Imaging center services provide diagnostic imaging services through flagship imaging centers, while imaging solutions assist healthcare institutions in selecting and procuring suitable imaging equipment [2].

Core Viewpoint - The launch of the AIR product by Yipai Yangguang marks a significant milestone in the medical imaging AI sector, transitioning from the 1.0 era of single-disease models to the 2.0 era driven by large foundational models, enhancing diagnostic capabilities across multiple organs and diseases [4] Company Summary - Yipai Yangguang, the largest third-party medical imaging center operator in China, experienced a stock price increase of over 7.1% initially, settling at a 1.91% rise to HKD 16.53 per share [3] - The AIR product, developed by the AI company Yinghe Yimai, is the first commercial outcome of the foundational model ecosystem, capable of simultaneous detection and diagnosis of multiple organs in a single chest CT scan [4] - The company aims to leverage its resources in medical imaging data and scenarios to enhance the performance of the foundational model and expand AI diagnostic products [4][5] Industry Summary - The third-party medical imaging service sector is recognized for its significant growth potential, supported by government policies encouraging the development of independent medical imaging centers [5] - The AI + medical imaging market in China is projected to exceed RMB 90 billion by 2025, with a compound annual growth rate (CAGR) of 58.3% from 2020 to 2025, significantly outpacing the global average [5] - The introduction of the AIR product is expected to strengthen Yipai Yangguang's core competitiveness in imaging center services, providing new momentum for the company's growth [5]

Market Overview - The Hang Seng Index fell by 1.61%, down 415 points, closing at 25,472 points, while the Hang Seng Tech Index dropped by 2.81%. The early trading volume in the Hong Kong market was HKD 153.2 billion [1] Energy Sector - Gas stocks rose, with Zhongyu Energy (03633) increasing by over 10%. This surge is attributed to the early initiation of winter heating in Gansu and other regions due to continuous temperature drops, leading to increased natural gas demand [1] Biotechnology Sector - Newly listed stock Xuan Zhu Bio-B (02575) surged over 13%, reaching a new high, and is up more than 190% from its IPO price. Yimai Sunshine (02522) rose over 4% following the global launch of its medical imaging model product AIR. The performance of medical stocks varied, with Yaojie Ankang-B (02617.HK) up over 21%, Baize Medical (02609) up over 5%, while Kangfang Biotech (09926) fell by 2%. Kangning Jereh Pharma-B (09966) increased by over 13% after announcing a share buyback plan, with market attention on significant data from the ESMO conference [2] Precious Metals Sector - Laopu Gold (06181) rose over 4%, benefiting from increased channel expansion and upgrades, with institutions indicating that rising gold prices favor its high-end brand positioning [3] Hospitality Sector - Wanda Hotel Development (00169) increased by over 10% after completing a sale and announcing a special dividend of HKD 0.462 per share to be paid next month [4] Digital Assets Sector - Delin Holdings (01709) rose over 3% after entering a strategic cooperation agreement with Antalpha to promote business in the digital asset sector [5] Telecommunications Sector - Changfei Optical Fiber and Cable (06869) fell over 6%, having dropped 40% from its September peak due to declining fiber optic prices and shareholder sell-offs. Cryptocurrency-related stocks collectively declined, with Bitcoin experiencing significant volatility and a recent incident in the US stablecoin market. Mi Strategy (02440) fell by 4.36%, and OSL Group (00863) dropped by 3.99% [6] Semiconductor Sector - Chip stocks continued to decline, with SMIC (00981) down over 5% and Huahong (01347) down over 3%, as US export controls accelerate domestic semiconductor replacements [6]

Group 1 - The stock of Yipai Yangguang (02522.HK) rose over 6% in early trading, reaching an increase of 6.23% at a price of 17.23 HKD [1] - The trading volume amounted to 80.63 million HKD [1]

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single-disease small models to the 2.0 era driven by a foundational large model, showcasing comprehensive diagnostic capabilities across multiple organs [1][2] Group 1 - Yimai Sunshine's stock rose over 6%, reaching HKD 17.23 with a trading volume of HKD 80.63 million following the announcement of the AIR product [1] - The AIR product is the first commercial outcome of the Yimai Medical's foundational large model ecosystem, designed to connect top hospitals with grassroots medical institutions through open interfaces [2] - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum from a single scan [1] Group 2 - The AIR product is expected to significantly shorten the AI product development cycle and reduce costs, facilitating standardized screening, intelligent diagnosis, and inclusive services in medical institutions [2] - The model promotes a positive feedback loop of "data-model-scenario" that enhances collaboration across the industry chain [2] - The technology behind the AIR product emphasizes efficient diagnosis, precise coverage, interactive collaboration, and seamless integration, fundamentally reconstructing the logic of medical imaging AI development and application [1]

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single disease small models to the 2.0 era driven by foundational large models, showcasing a milestone breakthrough in intelligent diagnosis [1][2] Group 1: Product Launch and Features - Yimai Sunshine's AIR product, developed by its incubated AI company Shanghai Yinghe Medical Technology, is the world's first AI-assisted diagnostic product based on a large medical imaging model [1] - The AIR product focuses on chest CT scans, enabling comprehensive detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - The product is built on the "Yinghe Mijia" model, which features multi-organ collaborative diagnosis capabilities, fundamentally restructuring the development and application logic of medical imaging AI [1] Group 2: Ecosystem and Market Impact - The AIR product serves as the first commercial outcome of the Yinghe Medical's foundational large model ecosystem, connecting top hospitals with grassroots medical institutions through open interfaces [2] - This model aims to create a positive cycle of "data feeding back model iteration, model driving scene implementation," significantly shortening AI product development cycles and reducing costs [2] - The initiative is expected to enhance screening standards, promote intelligent diagnosis, and facilitate inclusive services within the healthcare industry, effectively driving industry chain collaboration and establishing a "data-model-scene" closed-loop ecosystem [2]